New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer

NCT ID NCT07357727

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 6 times

Summary

This phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a placebo plus ruxolitinib. The main goals are to see if the combination shrinks the spleen and reduces symptoms like pain and fatigue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pelabresib (a drug) combined with ruxolitinib (a drug)
What this could lead to: If it works, this combination could offer better control of myelofibrosis by shrinking the spleen and easing symptoms more than the current standard treatment.
What could go wrong: This is a large phase 3 trial, but the added benefit of pelabresib is unproven. Side effects from the combination could be worse than ruxolitinib alone, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) PRIMARY MYELOFIBROSIS (PMF)

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Buenos Aires, Buenos Aires F.D., 1221, Argentina
Novartis Investigative Site
RECRUITING

Capital Federal, C1114AAN, Argentina
Novartis Investigative Site
RECRUITING

Clayton, Victoria, 3168, Australia
Novartis Investigative Site
RECRUITING

Hefei, Anhui, 230001, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Nantong, Jiangsu, 226000, China
Novartis Investigative Site
RECRUITING

Yantai, Shandong, 264000, China
Novartis Investigative Site
RECRUITING

Wenzhou, Zhejiang, 325000, China
Novartis Investigative Site
RECRUITING

Beijing, 100730, China
Novartis Investigative Site
RECRUITING

Chongqing, 400016, China
Novartis Investigative Site
RECRUITING

Fuzhou, 350001, China
Novartis Investigative Site
RECRUITING

Shenyang, 110004, China
Novartis Investigative Site
RECRUITING

Tianjin, 300020, China
Novartis Investigative Site
RECRUITING

Pune, Maharashtra, 411006, India
Novartis Investigative Site
RECRUITING

Kolkata, West Bengal, 700014, India
Novartis Investigative Site
RECRUITING

Johor Bahru, 80100, Malaysia
Novartis Investigative Site
RECRUITING

Kuala Selangor, 68000, Malaysia
Novartis Investigative Site
RECRUITING

Suwon, Gyeonggi-do, 442-723, South Korea
Novartis Investigative Site
RECRUITING

Jeonju, Jeollabuk-do, 54907, South Korea
Novartis Investigative Site
RECRUITING

Seoul, Yangcheon Gu, 07985, South Korea
Novartis Investigative Site
RECRUITING

Busan, 49241, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 03080, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 05505, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 06351, South Korea
Novartis Investigative Site
RECRUITING

Seoul, 06591, South Korea
Novartis Investigative Site
RECRUITING

Basel, 4058, Switzerland
Novartis Investigative Site
RECRUITING

Geneva, 1211, Switzerland
Novartis Investigative Site
RECRUITING

Genolier, 1272, Switzerland
Summit Medical Group Oncology
RECRUITING

Berkeley Heights, New Jersey, 07922, United States
The Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43221, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.